# Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders

> **NCT06068829** · — · UNKNOWN · sponsor: **Feng Jinzhou** · enrollment: 80 (estimated)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorders

## Interventions

- **DRUG:** Inebilizumab
- **DRUG:** Rituximab(RTX)

## Key facts

- **NCT ID:** NCT06068829
- **Lead sponsor:** Feng Jinzhou
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-20
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2023-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06068829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06068829, "Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06068829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*